<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Biochem Nutr</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Biochem Nutr</journal-id><journal-id journal-id-type="publisher-id">JCBN</journal-id><journal-title-group><journal-title>Journal of Clinical Biochemistry and Nutrition</journal-title></journal-title-group><issn pub-type="ppub">0912-0009</issn><issn pub-type="epub">1880-5086</issn><publisher><publisher-name>the Society for Free Radical Research Japan</publisher-name><publisher-loc>Kyoto, Japan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26060354</article-id><article-id pub-id-type="pmc">4454079</article-id><article-id pub-id-type="publisher-id">jcbn15-1</article-id><article-id pub-id-type="doi">10.3164/jcbn.15-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Long-term efficacy and safety of rabeprazole in patients taking low-dose
aspirin with a history of peptic ulcers: a phase 2/3, randomized, parallel-group,
multicenter, extension clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fujishiro</surname><given-names>Mitsuhiro</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Higuchi</surname><given-names>Kazuhide</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kato</surname><given-names>Mototsugu</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kinoshita</surname><given-names>Yoshikazu</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Iwakiri</surname><given-names>Ryuichi</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>Toshio</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Takeuchi</surname><given-names>Toshihisa</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sugisaki</surname><given-names>Nobuyuki</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Okada</surname><given-names>Yasushi</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Ogawa</surname><given-names>Hisao</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Arakawa</surname><given-names>Tetsuo</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Fujimoto</surname><given-names>Kazuma</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><collab collab-type="author">the PLANETARIUM Study Group</collab><xref ref-type="author-notes" rid="fn1">#</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Endoscopy and Endoscopic Surgery, Graduate
School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655,
Japan</aff><aff id="aff2"><label>2</label>Second Department of Internal Medicine, Osaka Medical
College, 2-7 Daigaku-cho, Takatsuki, Osaka 569-8686, Japan</aff><aff id="aff3"><label>3</label>Division of Endoscopy, Hokkaido University Hospital, Nishi
5-chome, Kita 14-jou, Kita-ku, Sapporo, Hokkaido 060-8648, Japan</aff><aff id="aff4"><label>4</label>Department of Internal Medicine II, Faculty of Medicine,
Shimane University, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan</aff><aff id="aff5"><label>5</label>Department of Internal Medicine &#x00026; Gastrointestinal
Endoscopy, Saga Medical School, 5-1-1 Nabeshima, Saga 849-8501, Japan</aff><aff id="aff6"><label>6</label>Department of Gastroenterology, Osaka City University
Graduate School of Medicine, 1-5-7 Asahi-cho, Abeno-ku, Osaka 545-8586, Japan</aff><aff id="aff7"><label>7</label>Clinical Development, Japan/Asia Clinical Research
Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 4-6-10
Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan</aff><aff id="aff8"><label>8</label>Clinical Research Institute and Cerebrovascular Medicine,
National Hospital Organization, Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-ku, Fukuoka
810-8563, Japan</aff><aff id="aff9"><label>9</label>Department of Cardiovascular Medicine, Graduate School of
Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556,
Japan</aff><aff id="aff10"><label>10</label>National Cerebral and Cardiovascular Center, 5-7-1
Fujishiro-dai, Suita, Osaka, 565-8565, Japan</aff><aff id="aff11"><label>11</label>Department of Internal Medicine, Saga Medical School,
5-1-1 Nabeshima, Saga 849-8501, Japan</aff><author-notes><corresp id="cor1">*To whom correspondence should be addressed. E-mail: <email>mtfujish-kkr@umin.ac.jp</email></corresp><fn id="fn1"><label>#</label><p>Other members of the PLANETARIUM Study Group are listed in the
Acknowledgments.</p></fn></author-notes><pub-date pub-type="ppub"><month>5</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>8</day><month>4</month><year>2015</year></pub-date><volume>56</volume><issue>3</issue><fpage>228</fpage><lpage>239</lpage><history><date date-type="received"><day>10</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 JCBN</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>A 24-week, double-blind, clinical trial of rabeprazole for the prevention of
recurrent peptic ulcers caused by low-dose aspirin (LDA) has been reported, but
trials for longer than 24 weeks have not been reported. The aim of this study is to
assess the long-term efficacy and safety of rabeprazole for preventing peptic ulcer
recurrence on LDA therapy. Eligible patients had a history of peptic ulcers on
long-term LDA (81 or 100&#x000a0;mg/day) therapy. Patients with no recurrence of
peptic ulcers at the end of the 24-week double-blind phase with rabeprazole (10- or
5-mg once daily) or teprenone (50&#x000a0;mg three times daily) entered the extension
phase. Rabeprazole doses were maintained for a maximum of 76 weeks, including the
double-blind 24-week period and the extension phase period (long-term rabeprazole 10-
and 5-mg groups). Teprenone was randomly switched to rabeprazole 10 or 5&#x000a0;mg for
a maximum of 52 weeks in the extension phase (newly-initiated rabeprazole 10- and
5-mg groups). The full analysis set consisted of 151 and 150 subjects in the
long-term rabeprazole 10- and 5-mg groups, respectively, and the cumulative
recurrence rates of peptic ulcers were 2.2 and 3.7%, respectively. Recurrent
peptic ulcers were not observed in the newly-initiated rabeprazole 10- and 5-mg
groups. No bleeding ulcers were reported. No clinically significant safety findings,
including cardiovascular events, emerged. The use of long-term rabeprazole 10- and
5-mg once daily prevents the recurrence of peptic ulcers in subjects on low-dose
aspirin therapy, and both were well-tolerated.</p></abstract><kwd-group><kwd>low-dose aspirin</kwd><kwd>peptic ulcer</kwd><kwd>bleeding ulcer</kwd><kwd>serious adverse events</kwd><kwd>rabeprazole</kwd></kwd-group></article-meta></front><body><sec sec-type="introduction"><title>Introduction</title><p>Low-dose aspirin (LDA) use reduces cardiovascular events by about 25% in
comparison to non-use, but increases gastrointestinal events two- to
five-fold.<sup>(<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B7" ref-type="bibr">7</xref>)</sup> A recent large-scale observational study
conducted in Japan found that 35.7% of patients using LDA to prevent the
occurrence of ischemic cardiac and cerebrovascular disease had gastroduodenal mucosal
injuries (6.5% ulcers and 29.2% erosions), and the risk of peptic ulcers
was particularly high in smokers and patients with <italic>Helicobacter pylori</italic>
(<italic>H. pylori</italic>) infections.<sup>(<xref rid="B8" ref-type="bibr">8</xref>)</sup> Other factors found to increase the risk of gastrointestinal events
include age greater than 70 years, history of upper gastrointestinal bleeding,
concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs), and antithrombotic
agents used alone or in combination with other antithrombotic drugs.<sup>(<xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>)</sup> LDA-induced gastroduodenal mucosal injuries must be vigilantly
managed because they are often asymptomatic and carry the risk of undetected
bleeding.<sup>(<xref rid="B12" ref-type="bibr">12</xref>)</sup> Histamine
H<sub>2</sub> receptor antagonists and proton pump inhibitors (PPIs) can be used with
LDA to reduce the occurrence of ulcers and erosions. PPIs, which potently suppress acid
secretion, are superior in this respect to histamine H<sub>2</sub> receptor
antagonists.<sup>(<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B13" ref-type="bibr">13</xref>)</sup> Several published guidelines and review articles
contain statements recommending concomitant PPI use for secondary prevention of
gastroduodenal mucosal injury associated with LDA therapy.<sup>(<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>)</sup></p><p>Rabeprazole, a PPI developed by Eisai Co., Ltd., exerts a rapid and potent inhibitory
effect on gastric acid secretion.<sup>(<xref rid="B16" ref-type="bibr">16</xref>)</sup>
The drug is efficacious in gastro-esophageal reflux disease (GERD) and other
acid-related diseases.<sup>(<xref rid="B17" ref-type="bibr">17</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>)</sup> Long-term use of rabeprazole was
confirmed to be safe in studies of two to five-year maintenance therapy for
GERD.<sup>(<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>)</sup>
Rabeprazole was recently found to reduce the incidence of esophageal and gastroduodenal
mucosal injury due to LDA therapy in healthy volunteers.<sup>(<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>)</sup> Furthermore,
rabeprazole affects CYP2C19 metabolic enzymes less than other PPIs,<sup>(<xref rid="B28" ref-type="bibr">28</xref>)</sup> and it minimally inhibit the
antiplatelet effects of LDA and clopidogrel.<sup>(<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>)</sup></p><p>Our recent 24-week, double-blind, comparative study (PLANETARIUM study) with a mucosal
protective agent as the control showed that rabeprazole (10 and 5&#x000a0;mg) was effective
and safe in the prevention of peptic ulcer recurrence in LDA users (the cumulative
recurrence rate of peptic ulcers at 24 weeks was 1.4% in the rabeprazole 10-mg
group, 2.8% in the rabeprazole 5-mg group and 21.7% in the teprenone
group). <sup>(<xref rid="B31" ref-type="bibr">31</xref>)</sup> Long-term Japanese data
over more than one year are available for the similar PPIs, lansoprazole and
esomeprazole,<sup>(<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>)</sup> but the data for rabeprazole extended only to 24
weeks.<sup>(<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B34" ref-type="bibr">34</xref>)</sup> Therefore, an extension phase study following the
24-week double-blind phase was performed to address this deficit. In the extension
phase, the subjects with no ulcer recurrence at week 24 of the double-blind phase were
given rabeprazole for another 28 to 52 weeks (for a total of 52 to 76 weeks of
treatment).</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>The study was a phase 2/3, randomized, parallel-group, multicenter, extension study
conducted from December 2011 to December 2013 at 62 medical institutions throughout
Japan (ClinicalTrials.gov Identifier: NCT01398410). The protocol of the extension study
was reviewed and approved concurrently with that of the preceding 24-week, double-blind
study by the institutional review boards of the participating medical institutions. The
subjects gave written, informed consent again before participating in the extension
study. The study was conducted in compliance with the ethical principles grounded in the
Declaration of Helsinki, as well as the Good Clinical Practice guideline of Japan.</p><sec><title>Study design</title><p>As shown in Fig.&#x000a0;<xref ref-type="fig" rid="F1">1</xref>, the 24-week,
double-blind phase contained three groups that received rabeprazole 10&#x000a0;mg once
daily, rabeprazole 5&#x000a0;mg once daily, or teprenone 50&#x000a0;mg three times daily.
The subjects allocated to the rabeprazole 10- and 5-mg groups in the double-blind
phase were maintained on the same doses of rabeprazole in the 28 to 52-week extension
phase, i.e., subjects were treated with rabeprazole for a 52 to 76-week period
consisting of the 24-week, double-blind phase and the extension phase (long-term
rabeprazole 10- and 5-mg groups). The subjects allocated to the teprenone group in
the double-blind phase were randomized to take rabeprazole 10- or 5-mg at a ratio of
1:1 in the 28 to 52-week extension phase (newly-initiated rabeprazole 10- and 5-mg
groups). The subjects not consenting to enter the extension phase were allowed to
conclude treatment at the end of the double-blind phase. The extension phase was
concluded for all subjects when the last subject in the extension phase completed
week 28. This meant that the subjects in the extension phase completed the study at a
variety of times from weeks 28 to 52. The key code was maintained double-blind in the
long-term rabeprazole 10- and 5-mg groups until July 11, 2013, and from this day on,
the key code was opened only for personnel of Eisai, the sponsor, but kept blinded to
the investigators, subinvestigators, clinical research coordinators, subjects, and
all others. The key code break was necessary for submission of the 24-week
double-blind data to the Pharmaceuticals and Medical Devices Agency (PMDA), the
Japanese authority, to obtain approval for a new indication for rabeprazole. On the
other hand, the extension phase of the newly-initiated rabeprazole 10- and 5-mg
groups concluded with double-blinding maintained.</p></sec><sec><title>Subjects</title><p>Patients with the following conditions were eligible for the double-blind
phase:<sup>(<xref rid="B31" ref-type="bibr">31</xref>)</sup> outpatients at
least 20 years of age who were on LDA (81 or 100&#x000a0;mg/day) therapy for
preventing thrombosis/embolization in cases of angina pectoris, myocardial
infarction, an ischemic cerebrovascular disorder, or similar condition and who had a
history of a gastric or duodenal ulcer but without a current acute gastroduodenal
mucosal lesion, gastric ulcer, or duodenal ulcer, upper gastrointestinal hemorrhage,
re&#x0fb02;ux esophagitis (modi&#x0fb01;ed Los Angeles Classi&#x0fb01;cation<sup>(<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>)</sup> Grade A or above), or Barrett&#x02019;s esophagus. Ulcer history
was determined by an endoscopy central review panel.<sup>(<xref rid="B31" ref-type="bibr">31</xref>)</sup> Subjects with no ulcer recurrence at the final
endoscopy of the double-blind phase (week 24) were entered into the extension phase
if the underlying cardiovascular or cerebrovascular disease was stable and continued
treatment with the same LDA dosage regimen was necessary.</p><p>Patients were eligible for study participation regardless of whether they were
<italic>H. pylori</italic>-positive or -negative. Presence of <italic>H.
pylori</italic> infection and CYP2C19 genotyping information were determined as
previously described.<sup>(<xref rid="B31" ref-type="bibr">31</xref>)</sup></p></sec><sec><title>Treatment</title><p>The study medications were prepared such that the active drugs were indistinguishable
in appearance from their corresponding placebo. In the extension phase, following a
double-dummy method, subjects in the rabeprazole 10-mg group received a rabeprazole
10&#x000a0;mg tablet and a rabeprazole 5&#x000a0;mg placebo tablet in the morning, while
subjects in the rabeprazole 5-mg group received a rabeprazole 5&#x000a0;mg tablet and a
rabeprazole 10&#x000a0;mg placebo tablet in the morning.</p><p>As in the double-blind phase, subjects in the extension phase were not allowed to
take drugs indicated for improving ulcers or gastrointestinal symptoms (e.g., PPIs
not used in the study, histamine H<sub>2</sub> receptor antagonists, prokinetics,
mucosal protective agents, antacids, prostaglandin agents, traditional Chinese herbal
medications) or atazanavir sulphate and rilpivirine hydrochloride, which are
contraindicated for concomitant use with rabeprazole. The concomitant use of non-LDA
anti-platelet drugs or anticoagulants was permitted.</p><p>To maintain independence, the tasks of study medication allocation and key code
retention were assigned to Bell Medical Solutions, Inc. (Tokyo, Japan), and the role
of subject enrolment center was assigned to EPS Corporation (Tokyo,
Japan).<sup>(<xref rid="B31" ref-type="bibr">31</xref>)</sup></p></sec><sec><title>Assessments</title><p>The subjects in the extension phase made hospital visits every four weeks. Upper
endoscopy was performed in the extension phase at week 28 and week 52 or at
discontinuation. If there were &#x0fb01;ndings suggestive of upper gastrointestinal
hemorrhage or intolerable upper gastrointestinal symptoms, additional upper endoscopy
was performed at the discretion of the investigator. If gastric or duodenal ulcers
were observed, the case was treated as a recurrence, and study participation was
terminated for that subject. Gastric and duodenal ulcers were rated based on the
Sakita-Miwa classification as:<sup>(<xref rid="B37" ref-type="bibr">37</xref>)</sup>
active stage (1, 2), healing stage (1, 2), or scar stage (1, 2). The Forrest
classification<sup>(<xref rid="B38" ref-type="bibr">38</xref>)</sup> was used
to assess the presence or absence of bleeding if an ulcer was observed: type I (a, b)
and type II (a, b) indicating bleeding, and type III indicating no bleeding. Reflux
esophagitis was assessed according to the modified Los Angeles Classification as: O
(without mucosal breaks) and A to D (with mucosal breaks). The modified Lanza score
was used to assess the severity of gastric or duodenal mucosal injury,<sup>(<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>)</sup> based on which gastric findings were rated from grade 0 (no
erosion, no ecchymosis) to 5 (ulcer), and duodenal findings from grade 0 (no erosion,
no ecchymosis) to 4 (ulcer). Laboratory tests were conducted and vital signs were
measured every 4 weeks. At each visit, subjects were also surveyed for compliance
with the study medications and LDA, the types of concomitant medications they were
taking, and the occurrence of any adverse events.</p></sec><sec><title>Efficacy evaluations</title><p>Efficacy was evaluated according to the following measures. The cumulative recurrence
rate of gastric or duodenal ulcers at the final evaluation (Kaplan-Meier life-table
estimates) was included in the main analysis of efficacy. An ulcer was defined as a
mucosal break measuring &#x02a7e;3&#x000a0;mm along its longest diameter with a white
coating.<sup>(<xref rid="B31" ref-type="bibr">31</xref>)</sup> The presence or
absence of ulcer recurrence was determined by the endoscopy central review panel
(panel of three endoscopy specialists: KH, MK, and MF) who were blinded to the
investigators&#x02019; assessments, based on endoscopy photos submitted by each of the
institutions. In cases of ulcer recurrence, the stage classification was assessed
(healing stage 2 or above). The following measures were included in the sub-analysis
of efficacy: cumulative incidence of bleeding ulcers at final evaluation (Forrest
Classification, type IIb or above), incidence of reflux esophagitis at final
evaluation (Grade A or above based on the modified Los Angeles Classification), and
percentage of subjects showing improvement/worsening of gastric mucosal injury
based on modified Lanza scores (improvement was defined as a decrease of at least 1
grade and worsening as an increase of at least 1 grade at the final assessment
compared to baseline).</p></sec><sec><title>Safety evaluations</title><p>Safety was evaluated based on adverse events, laboratory tests, and vital signs. The
incidences of treatment-emergent adverse events (TEAEs), serious adverse events, and
treatment-related adverse events were calculated in each treatment group. TEAEs were
defined as any untoward or unintended signs, symptoms or diseases, and/or
laboratory abnormalities that occurred after administration of a study drug. Serious
adverse events were defined as follows: deaths, life-threatening events,
hospitalization or prolongation of hospitalization for treatment, permanent or marked
disorder/dysfunction, congenital disease or abnormality, other events of medical
importance. Treatment-related adverse events were defined as any adverse events which
were judged to be related to the study drug. The incidences of TEAEs were evaluated
by age and by whether a non-LDA anti-platelet drug or anticoagulant was used. Serious
adverse events related to cardiovascular events (according to whether clopidogrel was
used), hemorrhage-related serious adverse events, adverse events related to bone
fractures, and adverse events related to pneumonia were evaluated as significant
adverse events in the context of combination therapy of LDA with PPI.</p></sec><sec><title>Statistical analysis</title><p>The number of subjects required for randomization in the double-blind phase was 150
per group or 450 totals in the three groups.<sup>(<xref rid="B31" ref-type="bibr">31</xref>)</sup> The sample sizes of the extension phase were set at 110 in
each of the long-term rabeprazole 10- and 5-mg groups (2 groups, 220 subjects) and 40
each in the newly-initiated rabeprazole 10- and 5-mg groups (2 groups, 80 subjects)
to account for subjects developing a recurrent ulcer or discontinuing the
double-blind phase and subjects not consenting to participate in the extension
phase.</p><p>Efficacy analyses were performed on the full analysis set. The full analysis set was
defined as all subjects who received at least one dose of rabeprazole, had results of
at least one post-initiation endoscopic assessment available, and showed no ulcers on
baseline endoscopy. Efficacy was evaluated separately in the long-term groups and
newly-initiated groups because of expected differences in the likelihood of these
groups developing ulcer recurrence. The safety analysis set was defined as all
subjects who received at least one dose of rabeprazole. Safety data of the long-term
rabeprazole 10- and 5-mg groups were combined with those of the newly-initiated
rabeprazole 10- and 5-mg groups to allow evaluation by dose for the safety
analyses.</p><p>Kaplan-Meier estimates were used to calculate the cumulative recurrence rates of
gastric or duodenal ulcers, and 95% confidence intervals were also calculated.
The cumulative incidence of bleeding ulcers was similarly analyzed. The frequencies
and summary statistics of the other efficacy and safety endpoints were calculated
according to the type and scale of the particular measure. TEAEs were tabulated using
ver. 15.1 of the Medical Dictionary for Regulatory Activities (MedDRA). Ischemic
heart disease, cardiac failure, and cerebrovascular disorders in the standardized
MedDRA queries (SMQs) were included in &#x0201d;cardiovascular-related adverse
events&#x0201d;. Similarly, hemorrhages in SMQs were included in
&#x0201d;hemorrhage-related adverse events&#x0201d;. All kinds of fractures were
included in &#x0201d;fracture-related adverse events&#x0201d;. Finally, aspiration
pneumonia often caused by an incompetent swallowing mechanism was excluded from
tabulations of pneumonia. All statistical analyses were performed using SAS software,
ver. 9.2 (SAS Institute, NC). Additionally, the following post-hoc analyses were
performed; for the cumulative recurrence rate of gastric or duodenal ulcers, the
log-rank test was used to check superiority of the rabeprazole 10-mg group as
compared with the rabeprazole 5-mg group. Stratified analysis of modified Lanza
scores by baseline (grade 0, grade &#x02a7e;1) was added. Fisher&#x02019;s exact test was
used to compare the rabeprazole 10- and 5-mg groups in the safety analysis.
<italic>P</italic> values of less than 0.05 were considered significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Demographics</title><p>The demographic and clinical characteristics of the safety analysis set are shown in
Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>. No characteristics differed
between the rabeprazole 10- and 5-mg groups. The heterogeneities in the history of
drugs for ulcer prevention, the presence of <italic>H. pylori</italic>, and
eradication history were similar between the groups.</p><p>The long-term rabeprazole 10- and 5-mg groups contained 158 and 156 subjects,
respectively, at the start of the double-blind phase, and 16 and 18 of these
subjects, respectively, were discontinued (Fig.&#x000a0;<xref ref-type="fig" rid="F2">2</xref>a). A total of 125 and 111 of these subjects, respectively, entered the
extension phase, and 20 and 8 of these subjects, respectively, were discontinued
(Fig.&#x000a0;<xref ref-type="fig" rid="F2">2</xref>a). The newly-initiated
rabeprazole 10- and 5-mg groups consisted of 47 and 45 subjects, respectively, who
received teprenone in the double-blind phase and were randomized to 10 or 5&#x000a0;mg
of rabeprazole in the extension phase, and 4 and 5 of these subjects, respectively,
were discontinued (Fig.&#x000a0;<xref ref-type="fig" rid="F2">2</xref>a). In both the
double-blind and extension phases, subjects were discontinued primarily for adverse
events or subject&#x02019;s choice.</p><p>Analysis sets are shown in Fig.&#x000a0;<xref ref-type="fig" rid="F2">2</xref>b.
Subjects were excluded from the full analysis set primarily for not having received
the study medications, lacking any evaluable endoscopy data after the start of
rabeprazole treatment, and for being ineligible due to having an ulcer at
baseline.</p><p>In the safety analysis set, the duration of study drug exposure
(mean&#x000a0;&#x000b1;&#x000a0;SD, min&#x02013;max) was 383.8&#x000a0;&#x000b1;&#x000a0;152.0 days
(2&#x02013;533 days) in the rabeprazole 10-mg group and 372.7&#x000a0;&#x000b1;&#x000a0;163.2
days (4&#x02013;538 days) in the rabeprazole 5-mg group. The mean compliance with study
medication was 99.4 and 99.2% in the 10- and 5-mg rabeprazole groups,
respectively. There were two subjects in the rabeprazole 5-mg group with less than
75% compliance with the study medication.</p></sec><sec><title>Efficacy</title><sec><title>Ulcer recurrence and incidence of bleeding ulcers.</title><p>Fig.&#x000a0;<xref ref-type="fig" rid="F3">3</xref> shows the Kaplan-Meier curves of
the cumulative recurrence rates of peptic ulcers in the long-term rabeprazole 10-
and 5-mg groups. At total week 76, the cumulative recurrence rates (%,
95% CI range, number of subjects) in the long-term groups were 2.2%
(0.72&#x02013;6.75, three subjects) in the 10-mg group and 3.7%
(1.53&#x02013;8.64, five subjects) in the 5-mg group (Kaplan-Meier estimates, full
analysis set). A significantly better preventive effect was not seen in the 10-mg
group compared to the 5-mg group (<italic>p</italic>&#x000a0;=&#x000a0;0.440).
After entering the extension phase, one subject in each of the rabeprazole 10- and
5-mg groups developed ulcer recurrence. In each patient, recurrence occurred at
total week 52. No bleeding ulcers were reported in either the long-term
rabeprazole 10- or 5-mg group at any time throughout the double-blind and
extension phases (i.e., to total week 76).</p><p>In the newly-initiated rabeprazole groups, no gastric or duodenal ulcers and no
bleeding ulcers were reported in either the rabeprazole 10- or 5-mg group at any
time during the extension phase (i.e., to week 52).</p></sec><sec><title>Details of subjects with ulcer recurrence in the long-term groups.</title><p>Background information and endoscopic details about all subjects with ulcer
recurrence are presented in Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>.
All subjects with a recurrent ulcer belonged to the long-term rabeprazole groups.
No subject in the newly-initiated rabeprazole groups had a recurrent ulcer. The
subjects with a recurrent ulcer had one or more previously-reported risk factors
for LDA ulcers (i.e., age &#x02a7e;70 years, <italic>H. pylori</italic>-positive,
history of upper gastrointestinal tract bleeding, use of anticoagulants, smoking,
alcohol consumption).</p></sec><sec><title>Erosive esophagitis.</title><p>The incidences of reflux esophagitis (number of subjects, grade) in the long-term
rabeprazole groups at the final evaluation were 0.7% (one subject, grade A)
in the 10-mg group and 0% (zero subjects) in the 5-mg group.</p><p>The incidences of reflux esophagitis in the newly-initiated rabeprazole groups at
the final evaluation were 2.1% (one subject, grade A) in the 10-mg group
and 0% (zero subjects) in the 5-mg group.</p></sec><sec><title>Severity scores of gastric damage.</title><p>The percentages of subjects showing improvement/worsening of gastric mucosal
injury based on modified Lanza scores are shown in Fig.&#x000a0;<xref ref-type="fig" rid="F4">4</xref>, where subjects in each of rabeprazole 10- and 5-mg groups
were separated in two sub-groups with grade 0 or grade &#x02a7e;1 at baseline. As the
figure shows, the percentages of subjects showing improvement/worsening were
similar between the 10-mg group and the 5-mg group, in both the long-term and
newly-initiated rabeprazole groups. On the other hand, the severity score of
duodenal damage at baseline was grade 0 in most subjects.</p></sec></sec><sec><title>Safety</title><p>In the safety evaluation, the data of the long-term groups and those of the
newly-initiated groups were combined and analyzed by rabeprazole doses.</p><sec><title>Treatment-emergent adverse events (TEAEs), treatment-related adverse
events.</title><p>TEAEs and treatment-related adverse events are summarized in Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>.</p><p>The incidences of TEAEs were 83.8% in the rabeprazole 10-mg group and
77.1% in the rabeprazole 5-mg group
(<italic>p</italic>&#x000a0;=&#x000a0;0.1031). In decreasing order, the most
common adverse events were nasopharyngitis, constipation, and diarrhoea in the
rabeprazole 10-mg group and nasopharyngitis, back pain, and contusion in the
rabeprazole 5-mg group.</p><p>The incidences of treatment-related adverse events were 13.7% in the
rabeprazole 10-mg group and 8.0% in the rabeprazole 5-mg group
(<italic>p</italic>&#x000a0;=&#x000a0;0.0785). The treatment-related adverse
events with an incidence of at least 2% were constipation only
(2.5%) in the rabeprazole 10-mg group and none in the 5-mg group.</p><p>The incidences of adverse events by age (&#x0003c;70 years, &#x02a7e;70 years) were
82.6% (76 of 92 subjects) and 84.8% (95 of 112 subjects),
respectively, in the rabeprazole 10-mg group and 78.7% (74 of 94 subjects)
and 75.7% (81 of 107 subjects), respectively, in the rabeprazole 5-mg
group. The incidences did not differ substantially in these age categories. The
incidences of adverse events by whether a non-LDA anti-platelet drug or
anticoagulant was used (used, not used) were 81.3% (39 of 48 subjects) and
84.6% (132 of 156 subjects), respectively, in the rabeprazole 10-mg group
and 83.3% (35 of 42 subjects) and 75.5% (120 of 159 subjects),
respectively, in the rabeprazole 5-mg group. Incidences were not consistently
higher in the subjects using non-LDA antithrombotics.</p></sec><sec><title>Serious adverse events.</title><p>Serious adverse events are summarized in Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>.</p><p>The incidences of serious adverse events were 14.7% in the rabeprazole
10-mg group and 16.4% in the rabeprazole 5-mg group
(<italic>p</italic>&#x000a0;=&#x000a0;0.6819). One death (completed suicide) was
reported in the rabeprazole 5-mg group but was considered causally unrelated to
the study medication. The serious adverse events reported in at least two subjects
were gastric cancer (four subjects) in the rabeprazole 10-mg group and angina
pectoris (three subjects), cataract (two subjects), and coronary artery restenosis
(two subjects) in the rabeprazole 5-mg group. The treatment-related serious
adverse events were acute cholecystitis (one subject) and gastrointestinal
hemorrhage (one subject) in the rabeprazole 10-mg group.</p></sec><sec><title>Significant adverse events.</title><p>The significant adverse events are summarized in Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>. The incidences of cardiovascular-related serious adverse
events in the safety analysis set were 2.0% (4/204) in the rabeprazole
10-mg group and 5.5% (11/201) in the rabeprazole 5-mg group
(<italic>p</italic>&#x000a0;=&#x000a0;0.0697). In detail, for the subjects who
took concomitant clopidogrel, the incidences in the rabeprazole 10- and 5-mg
groups were 0% (0/19) and 30.0% (6/20), respectively. For
the subjects who did not take concomitant clopidogrel, the incidences were
2.2% (4/185) and 2.8% (5/181), respectively. Thus, no
relationship was identified between rabeprazole dose and clopidogrel use.</p><p>The incidences of hemorrhage-related serious adverse events were 1.5%
(3/204) in the rabeprazole 10-mg group and 1.0% (2/201) in the
rabeprazole 5-mg group (<italic>p</italic>&#x000a0;=&#x000a0;1.000). Subdural
hematoma (one subject in the rabeprazole 10-mg group) was the only cerebrovascular
event.</p><p>A fracture-related adverse event occurred in six subjects (2.9%) in the
rabeprazole 10-mg group and seven subjects (3.5%) in the rabeprazole 5-mg
group (<italic>p</italic>&#x000a0;=&#x000a0;0.7858). A fracture-related serious
adverse event occurred in three subjects in the rabeprazole 10-mg group (spinal
compression fracture, femoral neck fracture, lower limb fracture) and in two
subjects in the rabeprazole 5-mg group (spinal compression fracture, femoral neck
fracture). A thoracic vertebral fracture (one subject in the rabeprazole 10-mg
group) was the only event assessed as treatment-related.</p><p>Pneumonia was not reported in either group.</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The prevention of peptic ulcer recurrence by rabeprazole in patients taking LDA had not
previously been investigated in a long-term (more than 24 weeks), randomized, clinical
trial. The present long-term administration trial evaluated the efficacy and safety of
treatment with rabeprazole for up to 76 weeks (total weeks of the double-blind and
extension phases) in subjects who showed no ulcer recurrence until the end of the
24-week double-blind phase.</p><p>The findings from this extension study were as follows: (1) once daily rabeprazole 10
and 5&#x000a0;mg were efficacious for preventing peptic ulcer recurrence for up to 76 weeks
in LDA users with a history of ulcers; (2) No cases of bleeding ulcer were seen not just
in the rabeprazole 10-mg group (standard dose in Japan), but also in the rabeprazole
5-mg group; and (3) the use of long-term rabeprazole and LDA posed no safety concerns
even in subjects taking clopidogrel, warfarin, and multiple other antithrombotic drugs
(who accounted for 23.5% of cases in the rabeprazole 10-mg group and 20.9%
of cases in the rabeprazole 5-mg group).</p><p>Recently, long-term studies of LDA&#x000a0;+&#x000a0;PPI using lansoprazole 15&#x000a0;mg
(study from Japan)<sup>(<xref rid="B32" ref-type="bibr">32</xref>)</sup> and
esomeprazole 20&#x000a0;mg (study from Japan, Korea and Taiwan)<sup>(<xref rid="B33" ref-type="bibr">33</xref>)</sup> were reported (lansoprazole 15&#x000a0;mg is half dose and
esomeprazole 20&#x000a0;mg is standard dose in Japan, respectively). The cumulative
occurrence rates in these studies [3.7% for lansoprazole (361 days) and
1.7% for esomeprazole (48 weeks)] were similar to the present cumulative
recurrence rates of 2.2% in the long-term rabeprazole 10-mg group and 3.7%
in the long-term rabeprazole 5-mg group. This finding shows that the ulcer
recurrence-preventing effect of rabeprazole is well-maintained for long periods. The
eight subjects who developed ulcer recurrence in the present study had at least one
previously-reported risk factor for LDA-induced ulcers,<sup>(<xref rid="B8" ref-type="bibr">8</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>)</sup> but no
common risk factor contributing to these recurrences was identified, possibly due to the
small recurrence number of cases.</p><p>The incidence of TEAEs was about 80% in the rabeprazole 10- and 5-mg groups. In
52-week studies of rabeprazole for GERD maintenance therapy, the incidences of adverse
events were also around 80%, with the commonly reported adverse events being
diarrhoea, nausea, abdominal pain, rhinitis, pharyngitis, and headache,<sup>(<xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B43" ref-type="bibr">43</xref>)</sup> which were similar to those in the present study. The incidences
of serious adverse events (about 15%) in the present study were also comparable
to those associated with GERD maintenance therapy. Hence, the types and frequencies of
adverse events in the present study were comparable to those in previous clinical
studies of rabeprazole without LDA therapy.</p><p>When taken together, clopidogrel and PPIs compete for CYP2C19, which reduces clopidogrel
efficacy and consequently increases cardiovascular events.<sup>(<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B45" ref-type="bibr">45</xref>)</sup> However, in
the prospective COGENT study of omeprazole, concomitant PPI and clopidogrel use reduced
upper gastrointestinal bleeding without increasing cardiovascular events, leading to the
conclusion that the two drugs can be used safely together.<sup>(<xref rid="B46" ref-type="bibr">46</xref>)</sup> A cross-over study of rabeprazole and omeprazole in
Japanese patients receiving aspirin and clopidogrel therapy due to prior percutaneous
coronary intervention showed that omeprazole significantly reduced the antiplatelet
effect of clopidogrel, and this effect on clopidogrel was stronger than that of
rabepazole.<sup>(<xref rid="B30" ref-type="bibr">30</xref>)</sup> Moreover, recent
reports found that, in dual antiplatelet therapy with aspirin and clopidogrel,
rabeprazole did not significantly affect the platelet aggregability of LDA and
clopidogrel<sup>(<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B47" ref-type="bibr">47</xref>,<xref rid="B48" ref-type="bibr">48</xref>)</sup> or increase
cardiovascular events.<sup>(<xref rid="B49" ref-type="bibr">49</xref>)</sup> In the
present study, about 95% of all subjects used LDA for secondary prevention and
9.6% (<italic>n</italic>&#x000a0;=&#x000a0;39) of all subjects had concomitant
administration of clopidogrel. Although the present incidence of serious cardiovascular
events in the subjects who used clopidogrel (15.4%, 6/39) was higher than
that in the subjects not taking clopidogrel (2.5%, 9/366) in the combined
rabeprazole groups (10 and 5&#x000a0;mg), no significant tendencies were identified that
suggested an interaction between rabeprazole dose and clopidogrel use. The incidence of
serious cardiovascular events (3.7%, 15 of 405 subjects) in the combined
rabeprazole groups (10 and 5&#x000a0;mg) did not exceed the 6.7% (per year)
incidence of serious cardiovascular events identified in a meta-analysis of aspirin in
secondary prevention.<sup>(<xref rid="B50" ref-type="bibr">50</xref>)</sup></p><p>Hemorrhagic events require special care in clinical practice. In addition to
gastrointestinal bleeding, intracranial bleeding is a notable adverse drug reaction to
LDA.<sup>(<xref rid="B51" ref-type="bibr">51</xref>)</sup> The 1.2%
incidence (5 of 405 subjects) of serious hemorrhage-related adverse events in the
combined rabeprazole groups (10 and 5&#x000a0;mg) did not differ greatly from the incidence
of severe bleeding in LDA users overall (5.58 per 1,000 persons/year).<sup>(<xref rid="B51" ref-type="bibr">51</xref>)</sup> Subdural hematoma, one kind of
intracranial bleeding, occurred in only one subject in the present study (incidence of
0.25% in the 10- and 5-mg groups combined). Therefore, there were no signs
suggesting that rabeprazole plus LDA promoted hemorrhage.</p><p>A prospective cohort study reported that chronic use of PPIs was associated with
increased risk of hip fracture, particularly among women with a history of
smoking.<sup>(<xref rid="B52" ref-type="bibr">52</xref>)</sup> A nested
case-control study and a meta-analysis indicated that long-term PPI therapy increased
the risk of hip fracture (adjusted odds ratio 1.44<sup>(<xref rid="B53" ref-type="bibr">53</xref>)</sup> and relative risk ratio 1.30,<sup>(<xref rid="B54" ref-type="bibr">54</xref>)</sup> respectively), but other studies did not find a causal
relationship between the use of PPI and an increased risk of bone fracture.<sup>(<xref rid="B55" ref-type="bibr">55</xref>,<xref rid="B56" ref-type="bibr">56</xref>)</sup> The incidence of all types of fracture-related adverse events in
the combined rabeprazole groups (10 and 5&#x000a0;mg) was 3.2% (13 of 405 subjects).
The incidence of fractures in the present long-term study was not high in the study
population, which had a mean age of 70 years (and a maximum age of 90 years), especially
considering that the prevalence of osteoporosis, femoral neck fractures, and vertebral
body fractures in Japan is much higher in people at least 60 years old.<sup>(<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B58" ref-type="bibr">58</xref>)</sup></p><p>Patients beginning to take PPIs were found to be at increased risk of community-acquired
pneumonia,<sup>(<xref rid="B59" ref-type="bibr">59</xref>)</sup> but no subject in
the present study developed pneumonia.</p><p>This study has several limitations. First, no comparator was used. Although the use of
the comparator teprenone in the 24-week double-blind phase facilitated strict
comparison, it was not ethically possible to establish a placebo or placebo-like control
group for the longer-term investigation. Second, blinding was compromised. Since the
data of the double-blind phase were submitted to the PMDA (Japanese regulatory
authority) before the completion of the extension phase, the key codes for the long-term
rabeprazole groups were unmasked in the extension phase to personnel of the sponsor,
Eisai, alone. However, blinding was maintained for the investigators and subjects in the
long-term rabeprazole groups, and double-blinding was maintained for the newly-initiated
rabeprazole groups throughout the study. These actions minimized bias and ensured data
reliability.</p><p>In conclusion, the findings of this extension study indicate that long-term rabeprazole
prevents ulcer recurrence very safely and efficaciously in LDA users.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank all contributing members and the sponsor, Japan/Asia
Clinical Research Product Creation Unit of Eisai Co., Ltd., Tokyo, Japan and the project
members of Mediscience Planning Inc., Tokyo, Japan for their contribution to study
monitoring.</p><p>This study was funded by Eisai Co., Ltd., Tokyo, Japan. Writing support was provided by
Eisai. Data management and analyses were undertaken by Eisai.</p><p>Members of the PLANETARIUM (<underline>P</underline>revention of recurrent gastric or
duodenal ulcers caused by <underline>L</underline>ow-dose
<underline>A</underline>spiri<underline>N</underline> with
rabeprazol<underline>E</underline>
<underline>T</underline>reatment -<underline>A</underline> multicenter,
<underline>R</underline>andom<underline>I</underline>zed, parallel-group,
do<underline>U</underline>ble-blind, co<underline>M</underline>parative trial-) study
group<sup>(<xref rid="B31" ref-type="bibr">31</xref>)</sup></p><p>Guarantor of the article: Kazuma Fujimoto.</p><sec><title>Author contributions:</title><p>Mitsuhiro Fujishiro, as an endoscopy specialist, was a member of the endoscopy
central review panel, and was involved in protocol planning, data interpretation, and
writing and editing the original paper. Kazuhide Higuchi and Mototsugu Kato, as
endoscopy specialists, were involved in protocol planning and data interpretation,
and were members of the endoscopy central review panel. Ryuichi Iwakiri, Toshio
Watanabe, and Toshihisa Takeuchi were involved in protocol planning, patient
recruitment, and data interpretation. Tetsuo Arakawa and Yoshikazu Kinoshita, as
specialists in gastroenterology, were involved in protocol planning, implementation
and overall coordination of the study, and data interpretation. Yasushi Okada and
Hisao Ogawa, as cerebrovascular and cardiovascular specialists, were involved in
protocol planning, implementation and overall coordination of the study, and data
interpretation. Nobuyuki Sugisaki was the sponsor&#x02019;s (Eisai Co., Ltd.) employee
in charge of this study. Kazuma Fujimoto, as the principal investigator, had overall
responsibility for the study. All authors reviewed this article and approved the
final version of the manuscript.</p><p>The PLANETARIUM study group contributed to acquisition of data. All members
introduced the patients to the experiments, received the agreements of all
participating patients.</p><p>Shoko Ono from Hokkaido University Hospital, Sapporo, Japan; Yutaka Suzuki from
Sapporo Ryokuai Hospital, Sapporo, Japan; Yusuke Saitoh and Masaki Taruishi from
Asahikawa City Hospital, Asahikawa, Japan; Tadashi Doi and Shinya Minami from Oji
General Hospital, Tomakomai, Japan; Masao Yamauchi from Yamauchi Medical Clinic,
Sapporo, Japan; Yasuhiro Nagaoka from Tokeidai Clinic, Sapporo, Japan; Toshiro
Kamoshida from Hitachi General Hospital, Hitachi, Japan; Hironori Masuyama from
Masuyama Gastrointestinal Clinic, Ohtawara, Japan; Motoyasu Kusano, Yasunori
Shimoyama and Osamu Kawamura from Gunma University Hospital, Maebashi, Japan; Naomi
Uemura from Kohnodai Hospital, Ichikawa, Japan; Masao Kobayakawa from National Center
for Global Health and Medicine, Tokyo, Japan; Kengo Tokunaga from Kyorin University
School of Medicine, Mitaka, Japan; Tomofumi Murakami from Shimokitazawa Tomo Clinic,
Tokyo, Japan; Masao Araki from Sagamihara Kyodo Hospital, Sagamihara, Japan; Takahiro
Takei from Fujisawa Shounandai Hospital, Fujisawa, Japan; Masahiko Inamori from
Yokohama City University Hospital, Yokohama, Japan; Seiji Otsuka from Koukan Clinic,
Kawasaki, Japan; Hiroaki Yamamoto from Nagano Chuo Hospital, Nagano, Japan; Naoshi
Nakamura from Marunouchi Hospital, Matsumoto, Japan; Taiji Akamatsu from Nagano
Prefectural Suzaka Hospital, Suzaka, Japan; Masahiko Onishi from Chikuma Central
Hospital, Chikuma, Japan; Masahiko Nakamura from Matsumoto City Hospital, Matsumoto,
Japan; Kuniharu Akita and Masaru Shimizu from Gifu Central Hospital, Gifu, Japan;
Takahisa Furuta and Mitsushige Sugimoto from Hamamatsu University School of Medicine,
Hamamatsu, Japan; Hiroki Yamanoue from Shizuoka Tokushukai Hospital, Shizuoka, Japan;
Akifumi Akai from Tokai Memorial Hospital, Kasugai, Japan; Takafumi Ando from Nagoya
University Graduate School of Medicine, Nagoya, Japan; Yuji Naito from Kyoto
Prefectural University of Medicine, Kyoto, Japan; Eiji Oyake from Uzumasa Medical
Clinic, Kyoto, Japan; Yasumasa Kondo from Clinic Horikawa, Kyoto, Japan; Keiichi
Kiriya and Masahiro Kido from Hirakata Kohsai Hospital, Hirakata, Japan; Toshihisa
Takeuchi from Osaka Medical College, Takatsuki, Japan; Makoto Sanomura from Hokusetsu
General Hospital, Takatsuki, Japan; Toshio Watanabe from Osaka City University
Graduate School of Medicine, Osaka, Japan; Takeshi Morita from Matsubara Tokushukai
Hospital, Matsubara, Japan; Hidemitsu Nakagawa from Nozaki Tokushukai Hospital,
Daito, Japan; Kokichi Asano from Yao Tokushukai General Hospital, Yao, Japan; Eijiro
Hayashi from Kinki Central Hospital, Itami, Japan; Takeshi Azuma from Kobe University
Graduate School of Medicine, Kobe, Japan; Kenji Furuta and Norihisa Ishimura from
Shimane University Faculty of Medicine, Izumo, Japan; Nobutoshi Kuniyoshi from
Kuniyoshi Hospital, Kochi, Japan; Hiroyuki Ikefuji from JA Kochi Hospital, Nankoku,
Japan; Naohiko Harada from Kyushu Medical Center, Fukuoka, Japan; Hideyuki Nomura
from Shin-Kokura Hospital, Kitakyushu, Japan; Tomoharu Yoshida from Kokura Memorial
Hospital, Kitakyushu, Japan; Kyota Higashi and Yasuhiro Ota from Fukuoka Wajiro
Hospital, Fukuoka, Japan; Toru Umezu from Umezu Clinic, Chikushino, Japan; Shigeru
Fujii from Fukuoka Shin Mizumaki Hospital, Fukuoka, Japan; Shinichi Ogata from
Saga-Ken Medical Centre Koseikan, Saga, Japan; Ryuichi Iwakiri from Saga Medical
School, Saga, Japan; Takahiro Noda from Karatsu Red Cross Hospital, Karatsu, Japan;
Seiji Tsunada from Ureshino Medical Center, Ureshino, Japan; Shin Suzuki from
Nagasaki Harbor Medical Center City Hospital, Nagasaki, Japan; Kazuhiko Nakao from
Nagasaki University Hospital, Nagasaki, Japan; Ikuo Matsushita from Kumamoto Chuo
Hospital, Kumamoto, Japan; Hibiki Ootani from Health Insurance Hitoyoshi General
Hospital, Hitoyoshi, Japan; Shinji Nasu from Oita Sanai Medical Center, Oita, Japan;
Kazunari Murakami from Oita University, Yuhu, Japan; Yasuhiko Gotoh from Shinbeppu
Hospital, Beppu, Japan; Shojiro Yamamoto from University of Miyazaki, Miyazaki,
Japan; Masataka Inakura from Inakura Clinic, Miyazaki, Japan; and Shou Nagai from
Ebino Sentro Clinic, Miyazaki, Japan.</p></sec></ack><glossary><title>Abbreviations</title><def-list><def-item><term>CABG</term><def><p>coronary artery bypass grafting</p></def></def-item><def-item><term>CYP2C19</term><def><p>cytochrome P450 isoenzyme</p></def></def-item><def-item><term>EM</term><def><p>extensive metabolizer</p></def></def-item><def-item><term>LDA</term><def><p>low-dose aspirin</p></def></def-item><def-item><term>MedDRA</term><def><p>Medical Dictionary for Regulatory Activities</p></def></def-item><def-item><term>PM</term><def><p>poor metabolizer</p></def></def-item><def-item><term>PMDA</term><def><p>Pharmaceuticals and Medical Devices Agency</p></def></def-item><def-item><term>PTCA</term><def><p>percutaneous transluminal coronary angioplasty</p></def></def-item><def-item><term>PPI</term><def><p>proton pump inhibitor</p></def></def-item><def-item><term>SMQs</term><def><p>standardized MedDRA queries</p></def></def-item><def-item><term>TEAE</term><def><p>treatment-emergent adverse event</p></def></def-item></def-list></glossary><sec><title>Conflict of Interest</title><p>Mitsuhiro Fujishiro has served in speaking and teaching commitments for Eisai Co., Ltd.
Kazuhide Higuchi has served in speaking and teaching commitments for Eisai Co., Ltd. and
Daiichi Sankyo Company, Ltd. and has received scholarship grants from Eisai Co., Ltd.,
and Daiichi Sankyo Company, Ltd. Mototsugu Kato has served in speaking and teaching
commitments for Eisai Co., Ltd., Daiichi Sankyo Company, Ltd., Takeda Pharmaceutical
Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and AstraZeneca K.K. and has received
scholarship grants from Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo
Company, Ltd., AstraZeneca K.K., and Astellas Pharma Inc. Yoshikazu Kinoshita has served
in speaking and teaching commitments in Eisai Co., Ltd., Daiichi Sankyo Company, Ltd.,
Takeda Pharmaceutical Co., Ltd. and AstraZeneca K.K. and has received research grants
and scholarship grants from Eisai Co., Ltd., Daiichi Sankyo Company, Ltd., Takeda
Pharmaceutical Co., Ltd. and AstraZeneca K.K. Toshio Watanabe has received research
grants from Eisai Co., Ltd. Nobuyuki Sugisaki is an employee of Eisai Co., Ltd. Hisao
Ogawa has served on advisory committees and review panels for Eli Lilly Japan K.K,
Novartis Pharma K.K., and Pfizer Japan Inc., has served as a board member of Takeda
Pharmaceutical Co., Ltd., has received research grants from AstraZeneca K.K., Astellas
Pharma Inc., Bayer Holding Ltd., Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd.,
Daiichi Sankyo Company, Ltd., Eisai Co., Ltd, Kowa Company, Ltd., Mitsubishi Tanabe
Pharma Corporation, MSD K.K., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd.,
Shionogi &#x00026; Co., Ltd., and Takeda Pharmaceutical Co., Ltd., and has served in
speaking and teaching commitments for Pfizer Japan Inc. and Sanofi K.K. Tetsuo Arakawa
has served on advisory committees and review panels for Eisai Co., Ltd, and Otsuka
Pharmaceutical Co., Ltd. Kazuma Fujimoto has served on advisory committees and review
panels for Eisai Co., Ltd.</p><p>The following authors have nothing to declare: Ryuichi Iwakiri, Toshihisa Takeuchi, and
Yasushi Okada.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Antithrombotic Trialists&#x02019; Collaboration</collab></person-group><article-title>Collaborative meta-analysis of randomised trials of
antiplatelet therapy for prevention of death, myocardial infarction, and stroke in
high risk
patients</article-title><source>BMJ</source><year>2002</year><volume>324</volume><fpage>71</fpage><lpage>86</lpage>
<comment>Erratum in: <italic>BMJ</italic> 2002; 324: 141</comment><pub-id pub-id-type="pmid">11786451</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasue</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effects of aspirin and trapidil on cardiovascular
events after acute myocardial infarction. Japanese Antiplatelets Myocardial
Infarction Study (JAMIS) Investigators</article-title><source>Am J
Cardiol</source><year>1999</year><volume>83</volume><fpage>1308</fpage><lpage>1313</lpage><pub-id pub-id-type="pmid">10235086</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisman</surname><given-names>SM</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name></person-group><article-title>Evaluation of the benefits and risks of low-dose
aspirin in the secondary prevention of cardiovascular and cerebrovascular
events</article-title><source>Arch Intern
Med</source><year>2002</year><volume>162</volume><fpage>2197</fpage><lpage>2202</lpage><pub-id pub-id-type="pmid">12390062</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nema</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Katsurada</surname><given-names>T</given-names></name><etal/></person-group><article-title>Endoscopic survey of low-dose-aspirin-induced
gastroduodenal mucosal injuries in patients with ischemic heart
disease</article-title><source>J Gastroenterol
Hepatol</source><year>2008</year><volume>23 Suppl
2</volume><fpage>S234</fpage><lpage>S236</lpage><pub-id pub-id-type="pmid">19120904</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>C</given-names></name><name><surname>Sugano</surname><given-names>K</given-names></name><name><surname>Ota</surname><given-names>S</given-names></name><etal/></person-group><article-title>Case-control study on the association of upper
gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in
Japan</article-title><source>Eur J Clin
Pharmacol</source><year>2006</year><volume>62</volume><fpage>765</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">16821007</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Iwakiri</surname><given-names>R</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><etal/></person-group><article-title>Low-dose aspirin is a prominent cause of bleeding
ulcers in patients who underwent emergency endoscopy</article-title><source>J
Gastroenterol</source><year>2009</year><volume>44</volume><fpage>912</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">19436943</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Tanigawa</surname><given-names>T</given-names></name><name><surname>Nadatani</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Mitochondrial disorders in NSAIDs-induced small bowel
injury</article-title><source>J Clin Biochem
Nutr</source><year>2011</year><volume>48</volume><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">21373263</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>N</given-names></name><name><surname>Sugano</surname><given-names>K</given-names></name><name><surname>Hiraishi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Risk factor profiles, drug usage, and prevalence of
aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese
patients: the results from the MAGIC study</article-title><source>J
Gastroenterol</source><year>2014</year><volume>49</volume><fpage>814</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">23754512</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanas</surname><given-names>A</given-names></name><name><surname>Scheiman</surname><given-names>J</given-names></name></person-group><article-title>Low-dose aspirin and upper gastrointestinal damage:
epidemiology, prevention and treatment</article-title><source>Curr Med Res
Opin</source><year>2007</year><volume>23</volume><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">17257477</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallas</surname><given-names>J</given-names></name><name><surname>Dall</surname><given-names>M</given-names></name><name><surname>Andries</surname><given-names>A</given-names></name><etal/></person-group><article-title>Use of single and combined antithrombotic therapy and
risk of serious upper gastrointestinal bleeding: population based case-control
study</article-title><source>BMJ</source><year>2006</year><volume>333</volume><fpage>726</fpage><pub-id pub-id-type="pmid">16984924</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiotani</surname><given-names>A</given-names></name><name><surname>Kamada</surname><given-names>T</given-names></name><name><surname>Haruma</surname><given-names>K</given-names></name></person-group><article-title>Low-dose aspirin-induced gastrointestinal diseases:
past, present, and future</article-title><source>J
Gastroenterol</source><year>2008</year><volume>43</volume><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">18709479</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeomans</surname><given-names>ND</given-names></name><name><surname>Lanas</surname><given-names>AI</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Prevalence and incidence of gastroduodenal ulcers
during treatment with vascular protective doses of
aspirin</article-title><source>Aliment Pharmacol
Ther</source><year>2005</year><volume>22</volume><fpage>795</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">16225488</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ib&#x000e1;&#x000f1;ez</surname><given-names>L</given-names></name><name><surname>Vidal</surname><given-names>X</given-names></name><name><surname>Vendrell</surname><given-names>L</given-names></name><etal/></person-group><article-title>Upper gastrointestinal bleeding associated with
antiplatelet drugs</article-title><source>Aliment Pharmacol
Ther</source><year>2006</year><volume>23</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">16393302</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>NS</given-names></name><name><surname>Hlatky</surname><given-names>MA</given-names></name><name><surname>Antman</surname><given-names>EM,</given-names></name><etal/><collab>ACCF/ACG/AHA</collab></person-group><article-title>ACCF/ACG/AHA 2010 expert consensus document on
the concomitant use of proton pump inhibitors and thienopyridines: a focused
update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the
gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the
American College of Cardiology Foundation Task Force on Expert
Consensus</article-title><source>Am J
Gastroenterol</source><year>2010</year><volume>105</volume><fpage>2533</fpage><lpage>2549</lpage><pub-id pub-id-type="pmid">21131924</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laine</surname><given-names>L</given-names></name><name><surname>Jensen</surname><given-names>DM</given-names></name></person-group><article-title>Management of patients with ulcer
bleeding</article-title><source>Am J
Gastroenterol</source><year>2012</year><volume>107</volume><fpage>345</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">22310222</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>K</given-names></name><name><surname>Kohata</surname><given-names>Y</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Intra-gastric pH following single oral administrations
of rabeprazole and esomeprazole: double-blind cross-over
comparison</article-title><source>J Clin Biochem
Nutr</source><year>2014</year><volume>55</volume><fpage>178</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">25411523</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>Y</given-names></name><name><surname>Ashida</surname><given-names>K</given-names></name><name><surname>Hongo</surname><given-names>M</given-names></name><collab>Japan Rabeprazole Study Group for NERD</collab></person-group><article-title>Randomised clinical trial: a multicenter, double-blind,
placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg
once daily in patients with non-erosive reflux
disease</article-title><source>Aliment Pharmacol
Ther</source><year>2011</year><volume>33</volume><fpage>213</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">21083596</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>T</given-names></name><name><surname>Shimatani</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Investigation of pretreatment prediction of proton pump
inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the
dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study
by the Acid-Related Symptom Research Group in Japan</article-title><source>J
Gastroenterol</source><year>2011</year><volume>46</volume><fpage>1273</fpage><lpage>1783</lpage><pub-id pub-id-type="pmid">21861141</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>Y</given-names></name><name><surname>Hongo</surname><given-names>M</given-names></name><collab>Japan TWICE Study Group</collab></person-group><article-title>Efficacy of twice-daily rabeprazole for reflux
esophagitis patients refractory to standard once-daily administration of PPI: the
Japan-based TWICE study</article-title><source>Am J
Gastroenterol</source><year>2012</year><volume>107</volume><fpage>522</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">22433921</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwakiri</surname><given-names>R</given-names></name><name><surname>Tominaga</surname><given-names>K</given-names></name><name><surname>Furuta</surname><given-names>K</given-names></name><etal/></person-group><article-title>Randomized clinical trial: rabeprazole improves
symptoms in patients with functional dyspepsia in
Japan</article-title><source>Aliment Pharmacol
Ther</source><year>2013</year><volume>38</volume><fpage>729</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">23957383</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Hongo</surname><given-names>M</given-names></name><collab>Maintenance Study Group</collab></person-group><article-title>Safety and efficacy of long-term maintenance therapy
with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux
esophagitis</article-title><source>Intern
Med</source><year>2011</year><volume>50</volume><fpage>179</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">21297318</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Umegaki</surname><given-names>E</given-names></name><name><surname>Takeuchi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Strategies for peptic ulcer healing after 1 week proton
pump inhibitor-based triple <italic>Helicobacter pylori</italic> eradication
therapy in Japanese patients: differences of gastric ulcers and duodenal
ulcers</article-title><source>J Clin Biochem
Nutr</source><year>2012</year><volume>51</volume><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">23170046</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Hongo</surname><given-names>M</given-names></name><collab>Maintenance Study Group</collab></person-group><article-title>Risk factors for relapse of erosive GERD during
long-term maintenance treatment with proton pump inhibitor: a prospective
multicenter study in Japan</article-title><source>J
Gastroenterol</source><year>2010</year><volume>45</volume><fpage>1193</fpage><lpage>1200</lpage><pub-id pub-id-type="pmid">20607308</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thjodleifsson</surname><given-names>B</given-names></name><name><surname>Rindi</surname><given-names>G</given-names></name><name><surname>Fiocca</surname><given-names>R</given-names></name><etal/></person-group><article-title>A randomized, double-blind trial of the efficacy and
safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the
maintenance of gastro-oesophageal reflux disease over 5
years</article-title><source>Aliment Pharmacol
Ther</source><year>2003</year><volume>17</volume><fpage>343</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">12562446</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caos</surname><given-names>A</given-names></name><name><surname>Breiter</surname><given-names>J</given-names></name><name><surname>Perdomo</surname><given-names>C</given-names></name><name><surname>Barth</surname><given-names>J</given-names></name></person-group><article-title>Long-term prevention of erosive or ulcerative
gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs.
placebo: results of a 5-year study in the United
States</article-title><source>Aliment Pharmacol
Ther</source><year>2005</year><volume>22</volume><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">16091056</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>M</given-names></name><name><surname>Nishino</surname><given-names>M</given-names></name><name><surname>Kodaira</surname><given-names>C</given-names></name><etal/></person-group><article-title>Esophageal mucosal injury with low-dose aspirin and its
prevention by rabeprazole</article-title><source>J Clin
Pharmacol</source><year>2010</year><volume>50</volume><fpage>320</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">19940233</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishino</surname><given-names>M</given-names></name><name><surname>Sugimoto</surname><given-names>M</given-names></name><name><surname>Kodaira</surname><given-names>C</given-names></name><etal/></person-group><article-title>Relationship between low-dose aspirin-induced gastric
mucosal injury and intragastric pH in healthy
volunteers</article-title><source>Dig Dis
Sci</source><year>2010</year><volume>55</volume><fpage>1627</fpage><lpage>1636</lpage><pub-id pub-id-type="pmid">19672708</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodaira</surname><given-names>C</given-names></name><name><surname>Uchida</surname><given-names>S</given-names></name><name><surname>Yamade</surname><given-names>M</given-names></name><etal/></person-group><article-title>Influence of different proton pump inhibitors on
activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath
test</article-title><source>J Clin
Pharmacol</source><year>2012</year><volume>52</volume><fpage>432</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">21415279</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uotani</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>M</given-names></name><name><surname>Nishino</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ability of rabeprazole to prevent gastric mucosal
damage from clopidogrel and low doses of aspirin depends on CYP2C19
genotype</article-title><source>Clin Gastroenterol
Hepatol</source><year>2012</year><volume>10</volume><fpage>879</fpage><lpage>885.e2</lpage><pub-id pub-id-type="pmid">22542748</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamane</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Tazaki</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of PPIs and an H<sub>2</sub> blocker on the
antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet
therapy</article-title><source>J Atheroscler
Thromb</source><year>2012</year><volume>19</volume><fpage>559</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">22472213</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwakiri</surname><given-names>R</given-names></name><name><surname>Higuchi</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><etal/></person-group><article-title>Randomised clinical trial: prevention of recurrence of
peptic ulcers by rabeprazole in patients taking low-dose
aspirin</article-title><source>Aliment Pharmacol
Ther</source><year>2014</year><volume>40</volume><fpage>780</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">25100080</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugano</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Itabashi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Lansoprazole for secondary prevention of gastric or
duodenal ulcers associated with long-term low-dose aspirin therapy: results of a
prospective, multicenter, double-blind, randomized, double-dummy,
active-controlled trial</article-title><source>J
Gastroenterol</source><year>2011</year><volume>46</volume><fpage>724</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">21499703</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugano</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>MG</given-names></name><name><surname>Lin</surname><given-names>JT</given-names></name><etal/><collab>LAVENDER Study Group</collab></person-group><article-title>Multinational, double-blind, randomised,
placebo-controlled, prospective study of esomeprazole in the prevention of
recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER
study</article-title><source>Gut</source><year>2014</year><volume>63</volume><fpage>1061</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">24326741</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanuki</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Kutsumi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Rabeprazole reduces the recurrence risk of peptic
ulcers associated with low-dose aspirin in patients with cardiovascular or
cerebrovascular disease: a prospective randomized active-controlled
trial</article-title><source>J
Gastroenterol</source><year>2012</year><volume>47</volume><fpage>1186</fpage><lpage>1197</lpage><pub-id pub-id-type="pmid">22526273</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshihara</surname><given-names>Y</given-names></name></person-group><article-title>Endoscopic findings of
GERD</article-title><source>Nihon
Rinsho</source><year>2004</year><volume>62</volume><fpage>1459</fpage><lpage>1464</lpage><comment>
(in Japanese)</comment><pub-id pub-id-type="pmid">15344535</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hongo</surname><given-names>M</given-names></name></person-group><article-title>Minimal changes in reflux esophagitis: red ones and
white ones</article-title><source>J
Gastroenterol</source><year>2006</year><volume>41</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">16568367</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>E</given-names></name><name><surname>Hoshihara</surname><given-names>Y</given-names></name><name><surname>Sakaki</surname><given-names>N</given-names></name><etal/></person-group><article-title>Peptic ulcer recurrence during maintenance therapy with
H<sub>2</sub>-receptor antagonist following first-line therapy with proton pump
inhibitor</article-title><source>J
Gastroenterol</source><year>2000</year><volume>35</volume><fpage>824</fpage><lpage>831</lpage><pub-id pub-id-type="pmid">11085491</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heldwein</surname><given-names>W</given-names></name><name><surname>Schreiner</surname><given-names>J</given-names></name><name><surname>Pedrazzoli</surname><given-names>J</given-names></name><name><surname>Lehnert</surname><given-names>P</given-names></name></person-group><article-title>Is the Forrest classification a useful tool for
planning endoscopic therapy of bleeding peptic
ulcers?</article-title><source>Endoscopy</source><year>1989</year><volume>21</volume><fpage>258</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">2693077</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanza</surname><given-names>FL</given-names></name><name><surname>Royer</surname><given-names>GL</given-names><suffix>Jr</suffix></name><name><surname>Nelson</surname><given-names>RS</given-names></name><name><surname>Chen</surname><given-names>TT</given-names></name><name><surname>Seckman</surname><given-names>CE</given-names></name><name><surname>Rack</surname><given-names>MF</given-names></name></person-group><article-title>A comparative endoscopic evaluation of the damaging
effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal
mucosa</article-title><source>Am J
Gastroenterol</source><year>1981</year><volume>75</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">7234826</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanza</surname><given-names>F</given-names></name><name><surname>Peace</surname><given-names>K</given-names></name><name><surname>Gustitus</surname><given-names>L</given-names></name><name><surname>Rack</surname><given-names>MF</given-names></name><name><surname>Dickson</surname><given-names>B</given-names></name></person-group><article-title>A blinded endoscopic comparative study of misoprostol
versus sucralfate and placebo in the prevention of aspirin-induced gastric and
duodenal ulceration</article-title><source>Am J
Gastroenterol</source><year>1988</year><volume>83</volume><fpage>143</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">3124604</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thjodleifsson</surname><given-names>B</given-names></name><name><surname>Beker</surname><given-names>JA</given-names></name><name><surname>Dekkers</surname><given-names>C</given-names></name><name><surname>Bjaaland</surname><given-names>T</given-names></name><name><surname>Finnegan</surname><given-names>V</given-names></name><name><surname>Humphries</surname><given-names>TJ</given-names></name></person-group><article-title>Rabeprazole versus omeprazole in preventing relapse of
erosive or ulcerative gastroesophageal reflux disease: a double-blind,
multicenter, European trial. The European Rabeprazole Study
Group</article-title><source>Dig Dis
Sci</source><year>2000</year><volume>45</volume><fpage>845</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">10795744</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caos</surname><given-names>A</given-names></name><name><surname>Moskovitz</surname><given-names>M</given-names></name><name><surname>Dayal</surname><given-names>Y</given-names></name><name><surname>Perdomo</surname><given-names>C</given-names></name><name><surname>Niecestro</surname><given-names>R</given-names></name><name><surname>Barth</surname><given-names>J</given-names></name></person-group><article-title>Rabeprazole for the prevention of pathologic and
symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease.
Rebeprazole Study Group</article-title><source>Am J
Gastroenterol</source><year>2000</year><volume>95</volume><fpage>3081</fpage><lpage>3088</lpage><pub-id pub-id-type="pmid">11095321</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birbara</surname><given-names>C</given-names></name><name><surname>Breiter</surname><given-names>J</given-names></name><name><surname>Perdomo</surname><given-names>C</given-names></name><name><surname>Hahne</surname><given-names>W</given-names></name></person-group><article-title>Rabeprazole for the prevention of recurrent erosive or
ulcerative gastro-oesophageal reflux disease. Rabeprazole Study
Group</article-title><source>Eur J Gastroenterol
Hepatol</source><year>2000</year><volume>12</volume><fpage>889</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">10958216</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilard</surname><given-names>M</given-names></name><name><surname>Arnaud</surname><given-names>B</given-names></name><name><surname>Cornily</surname><given-names>J-C</given-names></name><etal/></person-group><article-title>Influence of omeprazole on the antiplatelet action of
clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole
CLopidogrel Aspirin) study</article-title><source>J Am Coll
Cardiol</source><year>2008</year><volume>51</volume><fpage>256</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">18206732</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>PM</given-names></name><name><surname>Maddox</surname><given-names>TM</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Risk of adverse outcomes associated with concomitant
use of clopidogrel and proton pump inhibitors following acute coronary
syndrome</article-title><source>JAMA</source><year>2009</year><volume>301</volume><fpage>937</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">19258584</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Cryer</surname><given-names>BL</given-names></name><name><surname>Contant</surname><given-names>CF</given-names></name><etal/></person-group><article-title>Clopidogrel with or without omeprazole in coronary
artery disease</article-title><source>N Engl J
Med</source><year>2010</year><volume>363</volume><fpage>1909</fpage><lpage>1917</lpage><pub-id pub-id-type="pmid">20925534</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>Y</given-names></name><name><surname>Inomata</surname><given-names>J</given-names></name><name><surname>Kinoshita</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of proton pump inhibitors or famotidine on the
antiplatelet actions during dual-antiplatelet therapy in Japanese
patients</article-title><source>Cardiovasc Interv
Ther</source><year>2013</year><volume>28</volume><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">22886368</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funck-Brentano</surname><given-names>C</given-names></name><name><surname>Szymezak</surname><given-names>J</given-names></name><name><surname>Steichen</surname><given-names>O</given-names></name><etal/></person-group><article-title>Effects of rabeprazole on the antiplatelet effects and
pharmacokinetics of clopidogrel in healthy volunteers</article-title><source>Arch
Cardiovasc
Dis</source><year>2013</year><volume>106</volume><fpage>661</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">24246616</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hokimoto</surname><given-names>S</given-names></name><name><surname>Mizobe</surname><given-names>M</given-names></name><name><surname>Akasaka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Impact of CYP2C19 polymorphism and proton pump
inhibitors on platelet reactivity to clopidogrel and clinical outcomes following
stent implantation</article-title><source>Thromb
Res</source><year>2014</year><volume>133</volume><fpage>599</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">24440142</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Antithrombotic Trialists&#x02019; (ATT) Collaboration</collab><name><surname>Baigent</surname><given-names>C</given-names></name><name><surname>Blackwell</surname><given-names>L</given-names></name><etal/></person-group><article-title> Aspirin in the primary and secondary prevention of
vascular disease: collaborative meta-analysis of individual participant data from
randomised
trials</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>1849</fpage><lpage>1860</lpage><pub-id pub-id-type="pmid">19482214</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Berardis</surname><given-names>G</given-names></name><name><surname>Lucisano</surname><given-names>G</given-names></name><name><surname>D'Ettorre</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association of aspirin use with major bleeding in
patients with and without
diabetes</article-title><source>JAMA</source><year>2012</year><volume>307</volume><fpage>2286</fpage><lpage>2294</lpage><pub-id pub-id-type="pmid">22706834</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalili</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>ES</given-names></name><name><surname>Jacobson</surname><given-names>BC</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>Feskanich</surname><given-names>D</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name></person-group><article-title> Use of proton pump inhibitors and risk of hip fracture
in relation to dietary and lifestyle factors: a prospective cohort
study</article-title><source>BMJ</source><year>2012</year><volume>344</volume><fpage>e372</fpage><pub-id pub-id-type="pmid">22294756</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>YX</given-names></name><name><surname>Lewis</surname><given-names>JD</given-names></name><name><surname>Epstein</surname><given-names>S</given-names></name><name><surname>Metz</surname><given-names>DC</given-names></name></person-group><article-title>Long-term proton pump inhibitor therapy and risk of hip
fracture</article-title><source>JAMA</source><year>2006</year><volume>296</volume><fpage>2947</fpage><lpage>2953</lpage><pub-id pub-id-type="pmid">17190895</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>EW</given-names></name><name><surname>Bauer</surname><given-names>SR</given-names></name><name><surname>Bain</surname><given-names>PA</given-names></name><name><surname>Bauer</surname><given-names>DC</given-names></name></person-group><article-title>Proton pump inhibitors and risk of fractures: a
meta-analysis of 11 international studies</article-title><source>Am J
Med</source><year>2011</year><volume>124</volume><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">21605729</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngamruengphong</surname><given-names>S</given-names></name><name><surname>Leontiadis</surname><given-names>GI</given-names></name><name><surname>Radhi</surname><given-names>S</given-names></name><name><surname>Dentino</surname><given-names>A</given-names></name><name><surname>Nugent</surname><given-names>K</given-names></name></person-group><article-title>Proton pump inhibitors and risk of fracture: a
systematic review and meta-analysis of observational
studies</article-title><source>Am J
Gastroenterol</source><year>2011</year><volume>106</volume><fpage>1209</fpage><lpage>1218</lpage><pub-id pub-id-type="pmid">21483462</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodmer</surname><given-names>M</given-names></name><name><surname>Meier</surname><given-names>C</given-names></name><name><surname>Kraenzlin</surname><given-names>ME</given-names></name><name><surname>Meier</surname><given-names>CR</given-names></name></person-group><article-title>Proton pump inhibitors and fracture risk: true effect
or residual confounding?</article-title><source>Drug
Saf</source><year>2010</year><volume>33</volume><fpage>843</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">20812769</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orimo</surname><given-names>H</given-names></name><name><surname>Yaegashi</surname><given-names>Y</given-names></name><name><surname>Onoda</surname><given-names>T</given-names></name><name><surname>Fukushima</surname><given-names>Y</given-names></name><name><surname>Hosoi</surname><given-names>T</given-names></name><name><surname>Sakata</surname><given-names>K</given-names></name></person-group><article-title>Hip fracture incidence in Japan: estimates of new
patients in 2007 and 20-year trends</article-title><source>Arch
Osteoporos</source><year>2009</year><volume>4</volume><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">20234789</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatsuno</surname><given-names>I</given-names></name><name><surname>Terano</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lifestyle and osteoporosis in middle-aged and elderly
women: Chiba bone survey</article-title><source>Endocr
J</source><year>2013</year><volume>60</volume><fpage>643</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">23327841</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuliano</surname><given-names>C</given-names></name><name><surname>Wilhelm</surname><given-names>SM</given-names></name><name><surname>Kale-Pradhan</surname><given-names>PB</given-names></name></person-group><article-title>Are proton pump inhibitors associated with the
development of community-acquired pneumonia? A
meta-analysis</article-title><source>Expert Rev Clin
Pharmacol</source><year>2012</year><volume>5</volume><fpage>337</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">22697595</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig.&#x000a0;1</label><caption><p>Study design. The total number of weeks indicates the sum of the two treatment
periods in the double-blind phase and the extension phase of the long-term
rabeprazole groups. W indicates weeks.</p></caption><graphic xlink:href="jcbn15-1f01"/></fig><fig id="F2" position="float"><label>Fig.&#x000a0;2</label><caption><p>Subject disposition (a) and analysis sets (b). *Long-term rebeprazole groups,
**newly-initiated rebeprazole groups.</p></caption><graphic xlink:href="jcbn15-1f02"/></fig><fig id="F3" position="float"><label>Fig.&#x000a0;3</label><caption><p>Cumulative recurrence rates of peptic ulcers over 76 weeks in the long-term
rabeprazole groups (Kaplan-Meier estimates, full analysis set).</p></caption><graphic xlink:href="jcbn15-1f03"/></fig><fig id="F4" position="float"><label>Fig.&#x000a0;4</label><caption><p>Gastric mucosal damage (full analysis set). The percentages of subjects with
improvement/worsening of gastric mucosal injury based on modified Lanza scores
at the final assessment compared to baseline. Subjects in each of the rabeprazole
10- and 5-mg groups were separated in two sub-groups with grade 0 or grade &#x02265;1
at baseline.</p></caption><graphic xlink:href="jcbn15-1f04"/></fig><table-wrap id="T1" position="float"><label>Table&#x000a0;1</label><caption><p>Demographic and clinical characteristics (safety analysis set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Rabeprazole 10 mg
(<italic>n</italic>&#x000a0;=&#x000a0;204)</th><th align="center" rowspan="1" colspan="1">Rabeprazole 5&#x000a0;mg
(<italic>n</italic>&#x000a0;=&#x000a0;201)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Male,<italic> n</italic> (%)</td><td align="center" rowspan="1" colspan="1">152 (74.5)</td><td align="center" rowspan="1" colspan="1">153 (76.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean age&#x000a0;&#x000b1;&#x000a0;SD (min&#x02013;max), years</td><td align="center" rowspan="1" colspan="1">70.1&#x000a0;&#x000b1;&#x000a0;9.3 (40&#x02013;86)</td><td align="center" rowspan="1" colspan="1">69.4&#x000a0;&#x000b1;&#x000a0;8.5 (35&#x02013;90)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic conditions,<sup>a)</sup><italic>n</italic>
(%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Angina</td><td align="center" rowspan="1" colspan="1">81 (39.7)</td><td align="center" rowspan="1" colspan="1">88 (43.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Myocardial infarction</td><td align="center" rowspan="1" colspan="1">42 (20.6)</td><td align="center" rowspan="1" colspan="1">36 (17.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Ischemic cerebrovascular disease</td><td align="center" rowspan="1" colspan="1">98 (48.0)</td><td align="center" rowspan="1" colspan="1">99 (49.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CABG or PTCA</td><td align="center" rowspan="1" colspan="1">67 (32.8)</td><td align="center" rowspan="1" colspan="1">65 (32.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other</td><td align="center" rowspan="1" colspan="1">14 (6.9)</td><td align="center" rowspan="1" colspan="1">9 (4.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspirin dose</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;81&#x000a0;mg</td><td align="center" rowspan="1" colspan="1">19 (9.3)</td><td align="center" rowspan="1" colspan="1">16 (8.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;100&#x000a0;mg</td><td align="center" rowspan="1" colspan="1">185 (90.7)</td><td align="center" rowspan="1" colspan="1">185 (92.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of Aspirin use, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;2 years</td><td align="center" rowspan="1" colspan="1">49 (24.0)</td><td align="center" rowspan="1" colspan="1">50 (24.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;2 years</td><td align="center" rowspan="1" colspan="1">155 (76.0)</td><td align="center" rowspan="1" colspan="1">151 (75.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Concomitant use of antithrombotic drug other than aspirin,
<italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">48 (23.5)</td><td align="center" rowspan="1" colspan="1">42 (20.9)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Helicobacter pylori</italic> status,
<italic>n</italic> (%) (Anti-<italic>H. pylori</italic> IgG
antibodies)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Positive</td><td align="center" rowspan="1" colspan="1">90 (44.1)</td><td align="center" rowspan="1" colspan="1">92 (45.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Negative (with history of eradication)</td><td align="center" rowspan="1" colspan="1">71 (34.8)</td><td align="center" rowspan="1" colspan="1">57 (28.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Negative (without history of eradication)</td><td align="center" rowspan="1" colspan="1">43 (21.1)</td><td align="center" rowspan="1" colspan="1">52 (25.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">History of ulcers, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastric</td><td align="center" rowspan="1" colspan="1">123 (60.9)</td><td align="center" rowspan="1" colspan="1">140 (69.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Duodenal</td><td align="center" rowspan="1" colspan="1">79 (39.1)</td><td align="center" rowspan="1" colspan="1">61 (30.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;None</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">History of bleeding ulcers, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastric</td><td align="center" rowspan="1" colspan="1">10 (4.9)</td><td align="center" rowspan="1" colspan="1">12 (6.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Duodenal</td><td align="center" rowspan="1" colspan="1">8 (3.9)</td><td align="center" rowspan="1" colspan="1">7 (3.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">History of erosive esophagitis, <italic>n</italic>
(%)</td><td align="center" rowspan="1" colspan="1">25 (12.3)</td><td align="center" rowspan="1" colspan="1">35 (17.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mucosal injury at baseline with Modified Lanza score &#x02265;grade
1, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastric</td><td align="center" rowspan="1" colspan="1">56 (27.5)</td><td align="center" rowspan="1" colspan="1">51 (25.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Duodenal</td><td align="center" rowspan="1" colspan="1">7 (3.4)</td><td align="center" rowspan="1" colspan="1">2 (1.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">History of drug for prevention of ulcer, <italic>n</italic>
(%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PPIs</td><td align="center" rowspan="1" colspan="1">94 (46.1)</td><td align="center" rowspan="1" colspan="1">99 (49.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;H<sub>2</sub> receptor antagonists</td><td align="center" rowspan="1" colspan="1">49 (24.0)</td><td align="center" rowspan="1" colspan="1">54 (26.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mucosal protective agents</td><td align="center" rowspan="1" colspan="1">30 (14.7)</td><td align="center" rowspan="1" colspan="1">38 (18.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2C19 genotypes, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Homo EM</td><td align="center" rowspan="1" colspan="1">79 (38.7)</td><td align="center" rowspan="1" colspan="1">65 (32.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hetero EM</td><td align="center" rowspan="1" colspan="1">90 (44.1)</td><td align="center" rowspan="1" colspan="1">104 (51.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PM</td><td align="center" rowspan="1" colspan="1">35 (17.2)</td><td align="center" rowspan="1" colspan="1">32 (15.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoking, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">29 (14.2)</td><td align="center" rowspan="1" colspan="1">32 (15.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Current alcohol consumption, <italic>n</italic>
(%)</td><td align="center" rowspan="1" colspan="1">116 (56.9)</td><td align="center" rowspan="1" colspan="1">107 (53.2)</td></tr></tbody></table><table-wrap-foot><p>For the newly-initiated rabeprazole group, data of age, aspirin dose, concomitant
use of antithrombotic drug, modified Lanza score, current smoking and current
alcohol consumption were taken at the start of the extension phase.
<sup>a)</sup>Multiple choices allowed. CABG, coronary artery bypass grafting;
PTCA, percutaneous transluminal coronary angioplasty; CYP2C19, cytochrome P450
isoenzyme; EM, extensive metabolizer; PM, poor metabolizer.</p></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table&#x000a0;2</label><caption><p>Details of subjects with ulcer recurrence in the long-term groups (full analysis
set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Long-term group</th><th align="center" valign="middle" rowspan="1" colspan="1">Age (years)/Sex</th><th align="center" valign="middle" rowspan="1" colspan="1">LDA dose/LDA duration</th><th align="center" valign="middle" rowspan="1" colspan="1">Ischemic condition</th><th align="center" valign="middle" rowspan="1" colspan="1">Other anti-thromboticdrugs/<italic>H.
pylori</italic> status</th><th align="center" valign="middle" rowspan="1" colspan="1">History of bleeding ulcers/Erosive
esophagitis</th><th align="center" valign="middle" rowspan="1" colspan="1">History of drug/CYP2C19 genotype</th><th align="center" valign="middle" rowspan="1" colspan="1">Smoking/Alcohol habit</th><th align="center" valign="middle" rowspan="1" colspan="1">Time (days)* of ulcer
recurrence/Ulcer site</th><th align="center" valign="middle" rowspan="1" colspan="1">Ulcer Grade/Size/Number</th><th align="center" valign="middle" rowspan="1" colspan="1">Ulcer with bleeding/Erosive
esophagitis/GI symptoms</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rabeprazole 10&#x000a0;mg</td><td align="center" valign="middle" rowspan="1" colspan="1">64Male</td><td align="center" valign="middle" rowspan="1" colspan="1">81&#x000a0;mg2&#x02013;5 years</td><td align="center" valign="middle" rowspan="1" colspan="1">Angina</td><td align="center" valign="middle" rowspan="1" colspan="1">NoPositive</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNo</td><td align="center" valign="middle" rowspan="1" colspan="1">NoHetero EM</td><td align="center" valign="middle" rowspan="1" colspan="1">YesYes</td><td align="center" valign="middle" rowspan="1" colspan="1">161Gastric</td><td align="center" valign="middle" rowspan="1" colspan="1">H2 stage5&#x02013;15&#x000a0;mmMultiple</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNoNo</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rabeprazole 10&#x000a0;mg</td><td align="center" valign="middle" rowspan="1" colspan="1">75Male</td><td align="center" valign="middle" rowspan="1" colspan="1">100&#x000a0;mg&#x02265;5 years</td><td align="center" valign="middle" rowspan="1" colspan="1">AnginaPTCA</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes (ticlopidine)Positive</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNo</td><td align="center" valign="middle" rowspan="1" colspan="1">FamotidineHomo EM</td><td align="center" valign="middle" rowspan="1" colspan="1">NoYes</td><td align="center" valign="middle" rowspan="1" colspan="1">168Gastric</td><td align="center" valign="middle" rowspan="1" colspan="1">H1 stage3&#x02013;5&#x000a0;mmSingle</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNoNo</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rabeprazole 10&#x000a0;mg</td><td align="center" valign="middle" rowspan="1" colspan="1">64Male</td><td align="center" valign="middle" rowspan="1" colspan="1">100&#x000a0;mg2&#x02013;5 years</td><td align="center" valign="middle" rowspan="1" colspan="1">AnginaPTCA</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes (warfarin, clopidogrel)Negative</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNo</td><td align="center" valign="middle" rowspan="1" colspan="1">RabeprazoleHomo EM</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNo</td><td align="center" valign="middle" rowspan="1" colspan="1">364Gastric</td><td align="center" valign="middle" rowspan="1" colspan="1">H1 stage&#x02003;3&#x02013;5&#x000a0;mmSingle</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNoNo</td></tr><tr><td colspan="11" rowspan="1"><hr/></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rabeprazole 5&#x000a0;mg</td><td align="center" valign="middle" rowspan="1" colspan="1">55Male</td><td align="center" valign="middle" rowspan="1" colspan="1">81&#x000a0;mg&#x02265;5 years</td><td align="center" valign="middle" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNegative</td><td align="center" valign="middle" rowspan="1" colspan="1">NoYes</td><td align="center" valign="middle" rowspan="1" colspan="1">NoHetero EM</td><td align="center" valign="middle" rowspan="1" colspan="1">NoYes</td><td align="center" valign="middle" rowspan="1" colspan="1">78Gastric</td><td align="center" valign="middle" rowspan="1" colspan="1">A1 stage3&#x02013;5&#x000a0;mmMultiple</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNoNo</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rabeprazole 5&#x000a0;mg</td><td align="center" valign="middle" rowspan="1" colspan="1">67Male</td><td align="center" valign="middle" rowspan="1" colspan="1">100&#x000a0;mg&#x02265;5 years</td><td align="center" valign="middle" rowspan="1" colspan="1">Ischemic cerebrovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">NoPositive</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNo</td><td align="center" valign="middle" rowspan="1" colspan="1">RabeprazolePM</td><td align="center" valign="middle" rowspan="1" colspan="1">NoYes</td><td align="center" valign="middle" rowspan="1" colspan="1">91Gastric</td><td align="center" valign="middle" rowspan="1" colspan="1">A2 stage&#x02265;15&#x000a0;mmMultiple</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNoNo</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rabeprazole 5&#x000a0;mg</td><td align="center" valign="middle" rowspan="1" colspan="1">74Female</td><td align="center" valign="middle" rowspan="1" colspan="1">81&#x000a0;mg&#x02265;5 years</td><td align="center" valign="middle" rowspan="1" colspan="1">Ischemic cerebrovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNegative</td><td align="center" valign="middle" rowspan="1" colspan="1">NoYes</td><td align="center" valign="middle" rowspan="1" colspan="1">RanitidineHetero EM</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNo</td><td align="center" valign="middle" rowspan="1" colspan="1">161Gastric</td><td align="center" valign="middle" rowspan="1" colspan="1">H1 stage5&#x02013;15&#x000a0;mmSingle</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNoNo</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rabeprazole 5&#x000a0;mg</td><td align="center" valign="middle" rowspan="1" colspan="1">70Male</td><td align="center" valign="middle" rowspan="1" colspan="1">100&#x000a0;mg&#x02265;5 years</td><td align="center" valign="middle" rowspan="1" colspan="1">Ischemic cerebrovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNegative</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNo</td><td align="center" valign="middle" rowspan="1" colspan="1">LansoprazoleHetero EM</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNo</td><td align="center" valign="middle" rowspan="1" colspan="1">164Gastric</td><td align="center" valign="middle" rowspan="1" colspan="1">A2 stage5&#x02013;15&#x000a0;mmSingle</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNoNo</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rabeprazole 5&#x000a0;mg</td><td align="center" valign="middle" rowspan="1" colspan="1">59Female</td><td align="center" valign="middle" rowspan="1" colspan="1">100&#x000a0;mg2&#x02013;5 years</td><td align="center" valign="middle" rowspan="1" colspan="1">Ischemic cerebrovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes (warfarin)Negative</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNo</td><td align="center" valign="middle" rowspan="1" colspan="1">RabeprazoleHetero EM</td><td align="center" valign="middle" rowspan="1" colspan="1">NoYes</td><td align="center" valign="middle" rowspan="1" colspan="1">361Gastric</td><td align="center" valign="middle" rowspan="1" colspan="1">H1 stage3&#x02013;5&#x000a0;mmSingle</td><td align="center" valign="middle" rowspan="1" colspan="1">NoNoYes (Stomach discomfort)</td></tr></tbody></table><table-wrap-foot><p>LDA, low-dose aspirin; A1/A2 stage, active 1/2 stage; H1/H2 stage,
healing 1/2 stage. *Days were counted from the start of the 24-week
double-blind phase.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table&#x000a0;3</label><caption><p>Treatment-emergent adverse events (safety analysis set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Rabeprazole 10&#x000a0;mg
(<italic>n</italic>&#x000a0;=&#x000a0;204)</th><th align="center" rowspan="1" colspan="1">Rabeprazole 5&#x000a0;mg
(<italic>n</italic>&#x000a0;=&#x000a0;201)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Any treatment-emergent adverse events (TEAEs),
<italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">171 (83.8)</td><td align="center" rowspan="1" colspan="1">155 (77.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;5% TEAEs, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Nasopharyngitis</td><td align="center" rowspan="1" colspan="1">57 (27.9)</td><td align="center" rowspan="1" colspan="1">64 (31.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Constipation</td><td align="center" rowspan="1" colspan="1">16 (7.8)</td><td align="center" rowspan="1" colspan="1">9 (4.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Diarrhoea</td><td align="center" rowspan="1" colspan="1">16 (7.8)</td><td align="center" rowspan="1" colspan="1">11 (5.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Back pain</td><td align="center" rowspan="1" colspan="1">13 (6.4)</td><td align="center" rowspan="1" colspan="1">14 (7.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Eczema</td><td align="center" rowspan="1" colspan="1">12 (5.9)</td><td align="center" rowspan="1" colspan="1">6 (3.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Upper respiratory tract infection</td><td align="center" rowspan="1" colspan="1">10 (4.9)</td><td align="center" rowspan="1" colspan="1">10 (5.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Contusion</td><td align="center" rowspan="1" colspan="1">7 (3.4)</td><td align="center" rowspan="1" colspan="1">14 (7.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment-related adverse events, <italic>n</italic>
(%)</td><td align="center" rowspan="1" colspan="1">28 (13.7)</td><td align="center" rowspan="1" colspan="1">16 (8.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;2% Treatment-related adverse events,
<italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Constipation</td><td align="center" rowspan="1" colspan="1">5 (2.5)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Serious adverse events (SAEs), <italic>n</italic>
(%)</td><td align="center" rowspan="1" colspan="1">30 (14.7)</td><td align="center" rowspan="1" colspan="1">33 (16.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Death</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other SAEs*</td><td align="center" rowspan="1" colspan="1">30 (14.7)</td><td align="center" rowspan="1" colspan="1">32 (15.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Hospitalization</td><td align="center" rowspan="1" colspan="1">28 (13.7)</td><td align="center" rowspan="1" colspan="1">26 (12.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Persistent or significant
disability/incapacity</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Other important medical events</td><td align="center" rowspan="1" colspan="1">6 (2.9)</td><td align="center" rowspan="1" colspan="1">10 (5.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;2 serious adverse events, <italic>n</italic>
(%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Gastric cancer</td><td align="center" rowspan="1" colspan="1">4 (2.0)</td><td align="center" rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Angina pectoris</td><td align="center" rowspan="1" colspan="1">1 (0.5)</td><td align="center" rowspan="1" colspan="1">3 (1.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Cataract</td><td align="center" rowspan="1" colspan="1">1 (0.5)</td><td align="center" rowspan="1" colspan="1">2 (1.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Coronary artery restenosis</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">2 (1.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment-related serious adverse events,<italic> n</italic>
(%)</td><td align="center" rowspan="1" colspan="1">2 (1.0)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Acute cholecystitis</td><td align="center" rowspan="1" colspan="1">1 (0.5)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastrointestinal hemorrhage**</td><td align="center" rowspan="1" colspan="1">1 (0.5)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Significant adverse events, <italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cardiovascular-related serious adverse events</td><td align="center" rowspan="1" colspan="1">4 (2.0)</td><td align="center" rowspan="1" colspan="1">11 (5.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hemorrhage-related serious adverse events</td><td align="center" rowspan="1" colspan="1">3 (1.5)</td><td align="center" rowspan="1" colspan="1">2 (1.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Fracture-related adverse events</td><td align="center" rowspan="1" colspan="1">6 (2.9)</td><td align="center" rowspan="1" colspan="1">7 (3.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Pneumonia-related adverse events</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td></tr></tbody></table><table-wrap-foot><p>*Multiple choices allowed. **No gastric or duodenal ulcer recurrence
was reported.</p></table-wrap-foot></table-wrap></floats-group></article>